Page last updated: 2024-11-10

cucurbitacin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators
FloraRankFlora DefinitionFamilyFamily Definition
Ipomopsisgenus[no description available]Polemoniaceae[no description available]
Ipomopsis aggregataspecies[no description available]Polemoniaceae[no description available]

Cross-References

ID SourceID
PubMed CID5281316
CHEMBL ID508185
CHEBI ID3941
SCHEMBL ID231815
MeSH IDM0122413

Synonyms (59)

Synonym
19-norlanosta-5,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, [2.beta.,.gamma.,.beta.,10.alpha.,16.alpha.]-
nsc-49451
LMST01010104
19-nor-9-beta,10-alpha-lanosta-5,23-diene-3,11,22-trione, 2-beta,16-alpha,20,25-tetrahydroxy-9-methyl-, 25-acetate
cucurbitacine b
1,2-dihydro-alpha-elaterin
nsc 144154
19-nor-9beta,10alpha-lanosta-5,23-diene-3,11,22-trione, 2beta,16alpha,20,25-tetrahydroxy-9-methyl-, 25-acetate
25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-19-norlanosta-5,23-diene-3,11,22-trione
nsc 49451
19-norlanosta-5,23-diene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (2beta,9beta,10alpha,16alpha,23e)-
hsdb 3476
amarine
NSC49451 ,
6199-67-3
C08794
cucurbitacin b ,
19-nor-9.beta.,23-diene-3,11,22-trione, 9-methyl-2.beta.,16.alpha.,20,25-tetrahydroxy-, 25-acetate
nsc144154
cucurbitacin r - datisca principle b
datiscn principle b
19-norlanosta-5,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (2.beta.,9.beta.,10.alpha.,16.alpha.,23e)-
nsc-144154
datiscacin
datisca principle b
2beta,16alpha,20,25-tetrahydroxy-9-methyl-19-nor-9beta,10alpha-lanosta-5,23-diene-3,11,22-trione, 25-acetate
CHEBI:3941 ,
2beta,16alpha,20,25-tetrahydroxy-9-methyl-3,11,22-trioxo-19-nor-9beta,10alpha-lanosta-5,23-dien-25-yl acetate
(2s,4r,23e)-2,16beta,20-trihydroxy-9beta,10,14-trimethyl-1,11,22-trioxo-4,9-cyclo-9,10-secocholesta-5,23-dien-25-yl acetate
[(e,6r)-6-[(2s,8s,9r,10r,13r,14s,16r,17r)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-2,7,8,10,12,15,16,17-octahydro-1h-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl] acetate
CHEMBL508185
0115w5mabf ,
unii-0115w5mabf
cucurbitacin b hydrate
AKOS015897085
S8165
(+)-cucurbitacin b
19-norlanosta-5,23-diene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (2.beta.,9.beta.,10.alpha.,16.alpha.,23e)-
1,2-dihydro-.alpha.-elaterin
cucurbitacin b [inci]
(2.beta.,9.beta.,10.alpha.,16.alpha.,23e)-25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-19-norlanosta-5,23-diene-3,11,22-trione
cucurbitacin b [mi]
SCHEMBL231815
cucurbitacin-b
CS-3816
AC-34283
Q-100715
HY-N0416
cucurbitacin b hydrate, >=97% (hplc)
(3e,6r)-6-[(1r,2r,4s,10s,11s,13r,14r,15r)-4,13-dihydroxy-1,6,6,11,15-pentamethyl-5,17-dioxotetracyclo[8.7.0.0?,?.0??,??]heptadec-7-en-14-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate
mfcd07778083
(r,e)-6-((2s,8s,9r,10r,13r,14s,16r,17r)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate
Q27106259
C3442
CCG-270043
DTXSID501316196
(2beta,9beta,10alpha,16alpha,23e)-25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-19-norlanosta-5,23-diene-3,11,22-trione
A924078
gtpl12432

Research Excerpts

Overview

Cucurbitacin B (CuB) is a natural compound found in food plants such as bitter gourd and pumpkin. It manifests favorable antitumor effects on a variety of malignant tumors. There is relatively little research and application of this drug for lung cancer.

ExcerptReferenceRelevance
"Cucurbitacin B (CuB) is a class of tetracyclic triterpenoids isolated from Cucurbitaceae with a wide range of anti-inflammatory and anti-tumor activities, mainly used in hepatitis and hepatocellular carcinoma, while there is relatively little research and application of this drug for lung cancer. "( Antitumor activity and mechanism of cucurbitacin B in A549/DDP cells.
Chen, W; Cui, Q; Du, J; Gao, X; Lv, W; Song, Z; Yu, X; Zhang, J, 2023
)
2.63
"Cucurbitacin B (CuB) is a natural compound found in food plants such as bitter gourd and pumpkin, and it manifests favorable antitumor effects on a variety of malignant tumors."( Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
Liu, C; Mai, Z; Xia, C; Xu, L; Yin, S, 2023
)
1.84
"Cucurbitacin B is a natural compound widely distributed in the Cucurbitaceae and Cruciferae families and has many pharmacological activities."( Cucurbitacin B Exerts Significant Antidepressant-Like Effects in a Chronic Unpredictable Mild Stress Model of Depression: Involvement of the Hippocampal BDNF-TrkB System.
Chen, WJ; Ge, JB; Jiang, B; Li, WY; Qin, ZH; Shi, TS; Zhu, BL, 2023
)
3.07
"Cucurbitacin B (CuB) is a potent but toxic anticancer natural product. "( Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 against Non-Small Cell Lung Cancer.
Deng, H; Ding, C; Guo, H; Lin, T; Liu, W; Lu, Q; Pu, M; Quan, ZS; Shang, FF; Shen, QK; Xiao, R, 2023
)
2.62
"Cucurbitacin B (CuB) is a triterpenoid with potent biological properties."( Cucurbitacin B and erastin co-treatment synergistically induced ferroptosis in breast cancer cells via altered iron-regulating proteins and lipid peroxidation.
Bakar-Ates, F; Ozkan, E, 2024
)
3.61
"Cucurbitacin B (CuB) is a natural product with potent anti-cancer activities in solid tumors."( Cucurbitacin B inhibits gastric cancer progression by suppressing STAT3 activity.
Chen, Y; Guo, Y; Ke, W; Liu, X; Liu, Y; Si, Y; Xiang, K; Xu, J; Yang, R; Yang, S; Zhang, L; Zhang, T; Zhou, T, 2020
)
2.72
"Cucurbitacin B (CuB) is a widely available triterpenoid molecule that exhibits various biological activities. "( Induction of ferroptosis in human nasopharyngeal cancer cells by cucurbitacin B: molecular mechanism and therapeutic potential.
Cao, B; Chen, X; Feng, Y; Huang, S; Liang, B; Liao, S; Liu, J; Su, H; Wang, L; Yan, J; Zhang, J, 2021
)
2.3
"Cucurbitacin B (CuB) is a tetracyclic triterpene that possesses a potential anti-inflammatory activity."( NLRP3 inflammasome inhibitor cucurbitacin B suppresses gout arthritis in mice.
Fang, P; Li, L; Li, R; Xue, Y; Ye, ZQ; Zhang, KQ; Zhao, Y; Zhou, Y, 2021
)
1.63
"Cucurbitacin B (Cuc B) is a natural triterpenoid with potent anticancer activities while its effect on metastasis remains unclear."( Cucurbitacin B suppresses metastasis mediated by reactive oxygen species (ROS) via focal adhesion kinase (FAK) in breast cancer MDA-MB-231 cells.
Chen, XP; Lu, JJ; Luo, WW; Wang, YT; Zhao, WW, 2018
)
2.64
"Cucurbitacin B (CuB) is a natural tetracyclic triterpene product that displays antitumor activity against a wide variety of cancers. "( Cucurbitacin B suppresses proliferation of pancreatic cancer cells by ceRNA: Effect of miR-146b-5p and lncRNA-AFAP1-AS1.
Chen, Y; Guo, Y; Liu, M; Xu, S; Zhao, L; Zhou, J, 2019
)
3.4
"Cucurbitacin B (CuB) is a natural compound isolated from herbs and shows anticancer activity in several cancers."( Cucurbitacin B Inhibits the Hippo-YAP Signaling Pathway and Exerts Anticancer Activity in Colorectal Cancer Cells.
Chai, Y; Liu, X; Liu, Y; Si, Y; Wu, Y; Xiang, K; Zhang, T; Zhen, W, 2018
)
2.64
"Cucurbitacin B is a triterpenoid compound isolated from Trichosanthes kirilowii Maximowicz, which has been used in oriental medicine for its antitumor activities. "( Cucurbitacin B inhibits the translational expression of hypoxia-inducible factor-1α.
Jin, X; Joon Lee, J; Li, J; Ma, J; Mi, C; Shi, H; Wu, X; Xing Nan, J; Zi Jiang, Y, 2014
)
3.29
"Cucurbitacin B (CuB) is a naturally occurring compound that is found abundantly in cucumbers and other vegetables, and it is known to exert anti-cancer activities (primarily via apoptosis-induction) in several human cancers."( Inactivation of ATP citrate lyase by Cucurbitacin B: A bioactive compound from cucumber, inhibits prostate cancer growth.
Gao, Y; Islam, MS; Lui, VW; Tian, J; Xiao, D, 2014
)
1.4
"Cucurbitacin B (Cuc B) is a natural product with potent anti-cancer activities in solid tumors. "( Cucurbitacin B induces DNA damage, G2/M phase arrest, and apoptosis mediated by reactive oxygen species (ROS) in leukemia K562 cells.
Chen, X; Guo, J; Hao, W; Lu, J; Ren, G; Zhao, W, 2014
)
3.29
"Cucurbitacin B is a natural product and displays antitumor activity against a wide array of cancer cell lines."( Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.
Badria, FA; Chauhan, SC; El-Senduny, FF; El-Waseef, AM; Halaweish, F, 2016
)
1.39
"Cucurbitacin B is a plant-derived tetracyclic triterpenoid, which has been used for a variety of cancers, especially human hepatoma. "( Synergistic effect of cucurbitacin B in combination with curcumin via enhancing apoptosis induction and reversing multidrug resistance in human hepatoma cells.
Chen, D; Hu, H; Huang, Z; Qiao, M; Sun, Y; Zhang, J; Zhao, X; Zhou, J, 2015
)
2.17
"Cucurbitacin B (CuB) is a triterpenoid that is widely distributed in the plant kingdom and has a variety of biological activities. "( Cucurbitacin B inhibits immunomodulatory function and the inflammatory response in macrophages.
Jin, ML; Kim, M; Park, G; Park, SY; Son, HJ, 2015
)
3.3
"Cucurbitacin B is a natural anti-cancer compound found in Cucurbitaceae. "( Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562.
Chan, KT; Chu, KH; Li, K; Liu, SL; Toh, M; Xie, WD, 2010
)
3.25
"Cucurbitacin B (cucB) is a triterpenoid constituent of Cucurbitaceae vegetables and a promising phytochemical for cancer prevention. "( Cucurbitacin B induces G2 arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells.
Izutani, Y; Nakamura, Y; Sakai, T; Watanabe, H; Yasuda, S; Yogosawa, S, 2010
)
3.25
"Cucurbitacin B (CuB) is a member of the triterpenoid family and has shown inhibitory effect on various cancer cells."( Inhibition of pancreatic cancer cell growth by cucurbitacin B through modulation of signal transducer and activator of transcription 3 signaling.
Deng, Y; Li-Ling, J; Shan, X; Sun, C; Yang, X; Zhang, M, 2010
)
1.34

Effects

Cucurbitacin B has antiproliferative activity against various human breast cancer cells, but the molecular mechanism is not completely understood. The mechanism(s) initiating its biological effects remain largely unclear.

ExcerptReferenceRelevance
"Cucurbitacin B has the potential to be a novel antidepressant candidate."( Cucurbitacin B Exerts Significant Antidepressant-Like Effects in a Chronic Unpredictable Mild Stress Model of Depression: Involvement of the Hippocampal BDNF-TrkB System.
Chen, WJ; Ge, JB; Jiang, B; Li, WY; Qin, ZH; Shi, TS; Zhu, BL, 2023
)
3.8
"Cucurbitacin B has antiproliferative activity against various human breast cancer cells, but the molecular mechanism is not completely understood."( Cucurbitacin B Induces Hypermethylation of Oncogenes in Breast Cancer Cells.
Dakeng, S; Dittharot, K; Patmasiriwat, P; Promkan, M; Suebsakwong, P; Suksamrarn, A, 2019
)
2.68
"Cucurbitacin B (CuB), has recently emerged as a potent anticancer agent; however, its efficacy in non-small-cell lung cancer (NSCLC) and the mechanism(s) initiating its biological effects remain largely unclear. "( Cucurbitacin B potently suppresses non-small-cell lung cancer growth: identification of intracellular thiols as critical targets.
Aqil, F; Bansal, SS; Gupta, RC; Kausar, H; Munagala, R; Vadhanam, MV, 2013
)
3.28

Treatment

Cucurbitacin B (0.2-0.6 μM; 24 h) was found to result in decrease in the viability of EGFR-wild type (A549 and H1792), lung cancer cells (H1650 and H1975) and reduction in cell-colonies. Treatment had only minimal effect on normal human bronchial epithelial cells.

ExcerptReferenceRelevance
"Cucurbitacin B treatment inhibits lipid accumulation and expression of adipocyte markers including PPARγ and its target genes in a dose-dependent manner."( Cucurbitacin B and cucurbitacin I suppress adipocyte differentiation through inhibition of STAT3 signaling.
Ahn, JY; Cho, JY; Gwon, AR; Jo, DG; Nho, CW; Park, KW; Park, WJ; Seo, CR; Song, NJ; Yang, DK; Yang, SY; Yoon, K; Yun, UJ, 2014
)
2.57
"Cucurbitacin B treatment resulted in accumulation of cells at the S phase of cell cycle as well as apoptosis."( Targeted constitutive activation of signal transducer and activator of transcription 3 in human hepatocellular carcinoma cells by cucurbitacin B.
Deng, Y; Li-Ling, J; Shan, X; Sun, C; Yang, X; Zhang, H; Zhang, M, 2009
)
1.28
"Cucurbitacin B treatment inhibited translocation to the nucleus of β-catenin and galectin-3."( Inhibition of Wnt signaling by cucurbitacin B in breast cancer cells: reduction of Wnt-associated proteins and reduced translocation of galectin-3-mediated β-catenin to the nucleus.
Bögler, O; Dakeng, S; Duangmano, S; Jiratchariyakul, W; Patmasiriwat, P; U-Pratya, Y, 2012
)
1.39
"Treatment with cucurbitacin B (0.2-0.6 μM; 24 h) was found to result in decrease in the viability of EGFR-wild type (A549 and H1792) and EGFR-mutant lung cancer cells (H1650 and H1975) and reduction in cell-colonies but had only minimal effect on normal human bronchial epithelial cells."( Sestrin-3 modulation is essential for therapeutic efficacy of cucurbitacin B in lung cancer cells.
Jajeh, F; Khan, MI; Khan, N; Mukhtar, E; Mukhtar, H; Shabana, SM, 2017
)
1.04
"Treatment with cucurbitacin B resulted in cell cycle arrest at G2/M phase and the enhancement of apoptosis."( Cucurbitacin B inhibits human breast cancer cell proliferation through disruption of microtubule polymerization and nucleophosmin/B23 translocation.
Domann, FE; Duangmano, S; Patmasiriwat, P; Sae-Lim, P; Suksamrarn, A, 2012
)
2.16

Pharmacokinetics

ExcerptReferenceRelevance
" This assay was successfully applied to a pharmacokinetic study of CuB in Wistar rats."( Development and validation of a UPLC-MS/MS method for the determination of cucurbitacin B in rat plasma and application to a pharmacokinetic study.
Wang, Y; Xu, D; Yan, W; Zhang, N; Zhao, W, 2016
)
0.66
" The pharmacokinetic profile of this compound is still limited and investigation is needed for further phytopharmaceutical product development."( Pharmacokinetics of cucurbitacin B from Trichosanthes cucumerina L. in rats.
Hunsakunachai, N; Jiratchariyakul, W; Khemawoot, P; Kummalue, T; Nuengchamnong, N, 2019
)
0.84

Compound-Compound Interactions

ExcerptReferenceRelevance
" We aimed to investigate the apoptotic and antiproliferative effects of CuB as a single agent and in combination with Gef on both HT-29 and HCT-116 cell lines."( Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
Alp, E; Elmazoglu, Z; Menevse, S; Yar Saglam, AS, 2016
)
0.79
" In conclusion, cucurbitacin B in the combination with curcumin could serve as a novel, promising approach for human hepatoma."( Synergistic effect of cucurbitacin B in combination with curcumin via enhancing apoptosis induction and reversing multidrug resistance in human hepatoma cells.
Chen, D; Hu, H; Huang, Z; Qiao, M; Sun, Y; Zhang, J; Zhao, X; Zhou, J, 2015
)
1.08

Bioavailability

The absolute oral bioavailability of cucurbitacin B was approximately 10%. collagen cationic CPs were simply separated using ion-exchange resin from bovine CPs, to modify mixed nanomicelles (MMs) on the surface.

ExcerptReferenceRelevance
"69-fold increased in bioavailability as compared to conventional tablet formulation and 10."( Mucoadhesive buccal films containing phospholipid-bile salts-mixed micelles as an effective carrier for Cucurbitacin B delivery.
Han, J; Li, X; Lv, Q; Shen, B; Shen, C; Xu, H; Xu, P; Yu, C; Yuan, H, 2015
)
0.63
" The results indicated that the CUB-PLC-BER tended to provide a high and prolonged drug concentration to bile duct, and PL played a central role in internalizing CUB into cells to improve the water insoluble drug's permeability, which was of great benefit to enhance the bioavailability of CUB and improve therapeutic efficacy of CC."( Improve bile duct-targeted drug delivery and therapeutic efficacy for cholangiocarcinoma by cucurbitacin B loaded phospholipid complex modified with berberine hydrochloride.
Cheng, L; Han, J; Li, JJ; Liu, CY; Qiu, L; Shen, BD; Shen, G; Xu, PH; Yuan, HL, 2015
)
0.64
" Thus, in the present study, collagen cationic CPs were simply separated using ion-exchange resin from bovine CPs, to modify mixed nanomicelles (MMs) on the surface to improve the oral bioavailability of Cucurbitacin B (CuB)."( Modified mixed nanomicelles with collagen peptides enhanced oral absorption of Cucurbitacin B: preparation and evaluation.
Fu, L; Shan, W; Sun, B; Tang, L; Yang, Y; Zhang, Z; Zhu, Z, 2018
)
0.9
"The absolute oral bioavailability of cucurbitacin B was approximately 10%."( Pharmacokinetics of cucurbitacin B from Trichosanthes cucumerina L. in rats.
Hunsakunachai, N; Jiratchariyakul, W; Khemawoot, P; Kummalue, T; Nuengchamnong, N, 2019
)
1.11

Dosage Studied

ExcerptRelevanceReference
"27% for lower, moderate and higher dosage group, respectively."( [Effects of cucurbitacin B on cell proliferation and apoptosis in Hep-2 cells].
Deng, Y; Ji, W; Liu, T; Sun, C; Yang, X; Zhang, H; Zhang, M, 2008
)
0.72
" Dose-response studies showed that the drug inhibited 50% growth of seven pancreatic cancer cell lines at 10(-7) mol/L, whereas clonogenic growth was significantly inhibited at 5 x 10(-8) mol/L."( Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.
Abbassi, S; Doan, NB; Iwanski, GB; Koeffler, HP; Lin, P; Okamoto, R; Said, JW; Song, JH; Thoennissen, NH; Toh, M; Xie, WD; Yin, D, 2009
)
1.8
"The aim of this study was to investigate the feasibility of using spray granulation as a drying method to convert phospholipid (PL)-sodium deoxycholate (SDC)-mixed micelles (MMs) containing a water-insoluble drug to a solid dosage form and to evaluate how drugs with significantly different physicochemical properties affect the spray granulation process and subsequent in vitro and in vivo processes."( Application of spray granulation for conversion of mixed phospholipid-bile salt micelles to dry powder form: influence of drug hydrophobicity on nanoparticle reagglomeration.
Bai, J; Dai, L; Han, J; Li, X; Lv, Q; Shen, B; Shen, C; Xu, H; Yuan, H, 2014
)
0.4
" A plausible approach to address the tumor resistance is to co-administer the chemotherapeutic agents along with natural products to offer a synergistic effect and optimize the dosage regimen."( Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.
Badria, FA; Chauhan, SC; El-Senduny, FF; El-Waseef, AM; Halaweish, F, 2016
)
0.67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
cucurbitacinAny one of a class of tetracyclic triterpenoids, formally derived from the triterpene hydrocarbon cucurbitane, developed by some plants (especially those of the family Cucurbitaceaeas) as a defence mechanism against herbivores.
secondary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing one hydrogen and one organyl group. Secondary alpha-hydroxy ketones are also known as acyloins, and are formally derived from reductive coupling of two carboxylic acid groups.
tertiary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1415895Antimalarial activity against Plasmodium falciparum NF54 infected in human erythrocytes assessed as reduction in [3H]hypoxanthine incorporation preincubated for 48 hrs followed by [3H]hypoxanthine addition measured after 24 hrs by liquid scintillation cou2017MedChemComm, Jun-01, Volume: 8, Issue:6
Identification of steroid-like natural products as antiplasmodial agents by 2D and 3D similarity-based virtual screening.
AID1570848Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay2019ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10
A Bioreductive Prodrug of Cucurbitacin B Significantly Inhibits Tumor Growth in the 4T1 Xenograft Mice Model.
AID1570860Toxicity in BALB/c mouse implanted with mouse 4T1 cells assessed as death at 3 mg/kg/day, ip measured after 1 day2019ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10
A Bioreductive Prodrug of Cucurbitacin B Significantly Inhibits Tumor Growth in the 4T1 Xenograft Mice Model.
AID1386642Inhibition of AChE (unknown origin) at 10 uM using acetylthiocholine iodide as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by Ellman's method2018Journal of natural products, 09-28, Volume: 81, Issue:9
Colocynthenins A-D, Ring-A seco-Cucurbitane Triterpenoids from the Fruits of Citrullus colocynthis.
AID1570846Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2019ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10
A Bioreductive Prodrug of Cucurbitacin B Significantly Inhibits Tumor Growth in the 4T1 Xenograft Mice Model.
AID1683897Induction of LDR uptake in human HepG2 cells at 5 uM by DIL probe based fluorescence assay2020Journal of natural products, 12-24, Volume: 83, Issue:12
Lipid-Lowering Activities of Cucurbitacins Isolated from
AID1415896Cytotoxicity against CHO cells by MTT assay2017MedChemComm, Jun-01, Volume: 8, Issue:6
Identification of steroid-like natural products as antiplasmodial agents by 2D and 3D similarity-based virtual screening.
AID1415897Selectivity index, ratio of IC50 for CHO cells to IC50 for Plasmodium falciparum NF54 infected in human erythrocytes2017MedChemComm, Jun-01, Volume: 8, Issue:6
Identification of steroid-like natural products as antiplasmodial agents by 2D and 3D similarity-based virtual screening.
AID1408674Antiproliferative activity against human PC3 cells2018European journal of medicinal chemistry, Sep-05, Volume: 157ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.
AID1408675Antiproliferative activity against human LNCAP cells2018European journal of medicinal chemistry, Sep-05, Volume: 157ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.
AID1570847Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2019ACS medicinal chemistry letters, Oct-10, Volume: 10, Issue:10
A Bioreductive Prodrug of Cucurbitacin B Significantly Inhibits Tumor Growth in the 4T1 Xenograft Mice Model.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (172)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (1.16)18.7374
1990's4 (2.33)18.2507
2000's25 (14.53)29.6817
2010's100 (58.14)24.3611
2020's41 (23.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.80 (24.57)
Research Supply Index5.18 (2.92)
Research Growth Index5.56 (4.65)
Search Engine Demand Index44.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (3.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other170 (96.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]